BACKGROUND: The rapid evolution of SARS-CoV-2 continues to challenge vaccine effectiveness, particularly in elderly individuals at higher risk of severe disease. The World Health Organization has recommended the use of a monovalent JN.1 lineage vaccine antigen for updated COVID-19 vaccines since April 2024. It remains crucial to determine whether these JN.1-adapted vaccines induce cross-protective immunity against emerging variants, including KP.2, KP.3, XEC, XDV, LP.8.1, and NB.1.8.1. METHODS: A cohort of 62 participants (median age 63.5 years; 41 Comirnaty and 21 Spikevax recipients) was studied before and one month after JN.1 mRNA vaccination. Neutralizing antibody titres were assessed by surrogate virus neutralization test (sVNT) or plaque-reduction neutralization test (PRNT). T cell responses were analyzed by intracellular cytokine staining, and S2-specific antibody levels were quantified by ELISA. RESULTS: T cells. CONCLUSIONS: The monovalent JN.1 mRNA vaccines elicit broad cross-neutralizing and S2-directed humoral immunity in the elderly, though cellular responses remain heterogeneous. Continued monitoring and inclusion of conserved T cell epitopes in next-generation vaccine designs are warranted to sustain protection against future variants.
Tang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: